<DOC>
	<DOCNO>NCT01443728</DOCNO>
	<brief_summary>This study aim answer question whether oral vitamin D supplementation decrease lung complication child adolescent sickle cell disease . Lung complication lead cause morbidity death sickle cell disease . Infections increase inflammation play important role development lung problem sickle cell disease . Emerging evidence show vitamin D help immune system fight infection control inflammation could potentially help prevent respiratory complication patient sickle cell disease . The investigator hypothesize oral vitamin D3 , 100,000 IU ( 2.5 mg ) , give month group child adolescents sickle cell disease , reduce rate respiratory event ( infection , asthma exacerbation acute chest syndrome ) compare rate group give standard dose oral vitamin D3 , 12,000 IU ( 0.3 mg ) give month . Funding Source - U.S. Food &amp; Drug Administration , Office Orphan Products Development</brief_summary>
	<brief_title>Vitamin D Sickle-cell Respiratory Complications</brief_title>
	<detailed_description>This study Phase 2 double-blind randomized clinical trial 80 patient sickle cell disease , age 3 20 years-old , compare 2-year monthly oral dose vitamin D3 , 100,000 IU ( equivalent 3,300 IU/day ) standard monthly dose , 12,000 IU ( 400 IU/day ) reduce rate respiratory event ( define respiratory infection , acute asthma exacerbation , acute chest syndrome ) child adolescent sickle cell disease comparison rate respiratory event baseline period one year . Eligible participant ( 130 patient ) initially screen determine blood vitamin D level ( serum 25-hydroxyvitamin D ) . Those 25-hydroxyvitamin D level 5 60 ng/mL eligible randomization . At study entry , blood urine sample collect routine special blood test include test immune function , inflammation , bone function . Children 5 year old also lung function muscle strength test . Participants follow month administer study medication ( oral vitamin D3 ) monitor side effect study medication history , examination blood urine test . After 12 24 month therapy , study procedure study entry repeat . This study could help establish oral vitamin D3 simple , low cost treatment reduce respiratory complication child adolescent sickle cell disease .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Acute Chest Syndrome</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Diagnosis sickle cell disease ( HbSS , HbSC , HbS Betathalassemia ) Age 3 20 year old Patient ( parent guardian ) unwilling unable provide write informed consent ( assent , applicable ) Patient unable unwilling comply requirement clinical trial Participation therapeutic clinical trial Current diagnosis rickets History hypercalcemia diagnosis medical condition associate hypercalcemia , include primary hyperparathyroidism , malignancy , sarcoidosis , tuberculosis , granulomatous disease , familial hypocalciuric hypercalcemia Current use corticosteroid , exclude inhaled steroid Current use anticonvulsant ( phenytoin , phenobarbital , carbamazepine ) Therapy thiazide diuretic lithium carbonate Known liver renal disease Patients take medication pulmonary complication sickle cell disease stable dose medication , define change medication dos within three month prior study entry Patients chronic red blood cell transfusion therapy Absence baseline record respiratory event ( respiratory infection , asthma exacerbation , episode acute chest syndrome ) precede year Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>acute chest syndrome</keyword>
	<keyword>respiratory complication</keyword>
	<keyword>vitamin D</keyword>
</DOC>